Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study

June 19, 2020 updated by: Chien-Sheng Wu, Far Eastern Memorial Hospital
The incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. The relative impact of gene and environment on diseases can be revealed by studies from different populations. National Health Insurance database in Taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. However, national health care database did not contain test results and clinical details. The database of the hospital records can provide complimentary clinical details. Via the comparison of databases of the National health Institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood.

Study Overview

Status

Completed

Conditions

Detailed Description

The incidence and prevalence of the allergic, autoimmune and rheumatic diseases are different all over the world. The relative impact of gene and environment on diseases can be revealed by studies from different populations.

National Health Insurance database in Taiwan provides a wealth of epidemiology study, which can contribute to the understanding of these diseases. However, national health care database did not contain test results and clinical details. The database of the hospital records can provide complimentary clinical details. Via the comparison of databases of the National health Institutes and the investigators hospital, the investigators hope that the characteristics and outcomes of these patients can be better understood.

Briefly, epidemiology of target disease such as age, sex, incidence and prevalence will be derived from national database. Medical source utilization such as medication and surgery related to target diseases is also available in national database, providing material for cost analysis. These data can be compared with hospital database to ensure validity and reliability.

The investigators study is intended to provide epidemiology of target disease and cost analysis. Interaction between diseases will also be explored.

Target diseases Allergic diseases: Asthma(ICD9 493.x),Steven-Johnson syndrome and other erythroderma (ICD9 695.x)

Autoimmune diseases: Thyroid disease (ICD9 246.x), Addison disease (ICD9 255.x), type 1 diabetes mellitus (250.x1)

Rheumatic diseases: gout (ICD9 274.x), SLE (ICD9 710.0 ), RA (ICD9 714.0), AS and spondylitis (ICD9 720.0&720.x), Psoriasis and psoriatic arthritis (ICD9 696.0), scleroderma (ICD9 710.1), Sjogren's syndrome (ICD9 710.2), dermatomyositis (ICD9 710.3), polymyositis (ICD9 710.4), ANCA vasculitis (WG 446.4, MPA, CSS, PAN ICD9 446.0) or vasculitis 447.6, Behcet's disease(ICD9 136.1), Temporal arteritis(ICD9 446.5), Takayasu arteritis (ICD9 446.7), Henoch-Schonlein purpura (ICD9 287.0)

Study Type

Observational

Enrollment (Actual)

138

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • New Taipei City, Taiwan, 220
        • Far eastern memorial hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

National Health Insurance Research Database Far Eastern Memorial Hospital clinical database

Description

Inclusion Criteria:

  • subjects with ICD9 coding fulfilling study subjects

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of target diseases
Time Frame: Up to ten years
Population at risk of target diseases in database will be assessed up to 10 years
Up to ten years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Far Eastern Memorial Hospital

Investigators

  • Principal Investigator: ChienSheng Wu, Master, Chief, Department of Rheumatic disease

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2012

Primary Completion (Actual)

December 30, 2019

Study Completion (Actual)

December 30, 2019

Study Registration Dates

First Submitted

May 26, 2012

First Submitted That Met QC Criteria

June 4, 2012

First Posted (Estimate)

June 5, 2012

Study Record Updates

Last Update Posted (Actual)

June 23, 2020

Last Update Submitted That Met QC Criteria

June 19, 2020

Last Verified

June 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 100165-E

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No IPD sharing, only sharing by publication

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autoimmune Diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe